Haemonetics Corp. CEO Sells $316,008 in Stock (HAE)
Haemonetics Corp. (NYSE:HAE) CEO Brian Concannon sold 7,600 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $41.58, for a total value of $316,008.00. Following the transaction, the chief executive officer now directly owns 130,307 shares in the company, valued at approximately $5,418,165. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on HAE. Analysts at Benchmark Co. downgraded shares of Haemonetics Corp. from a “buy” rating to a “hold” rating in a research note to investors on Tuesday. They now have a $46.00 price target on the stock, down previously from $49.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Haemonetics Corp. in a research note to investors on Friday, December 27th. They now have a $45.00 price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of Haemonetics Corp. in a research note to investors on Tuesday, December 17th. They set a “sell” rating and a $39.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $44.83.
Shares of Haemonetics Corp. (NYSE:HAE) traded up 0.34% during mid-day trading on Friday, hitting $41.42. 121,915 shares of the company’s stock traded hands. Haemonetics Corp. has a 52-week low of $37.71 and a 52-week high of $45.90. The stock’s 50-day moving average is $42.09 and its 200-day moving average is $41.56. The company has a market cap of $2.134 billion and a P/E ratio of 68.80.
Haemonetics Corp. (NYSE:HAE) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.66 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.09. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $239.51 million. During the same quarter in the prior year, the company posted $0.90 earnings per share. The company’s quarterly revenue was up 7.7% on a year-over-year basis.
Haemonetics Corporation is a healthcare company. The Company is engaged developing and manufacturing automated blood component collection devices and surgical blood salvage devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.